Lung Cancer Dispatch
Follow
Find tag "DDR2"
3.6K views | +1 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

Researchers Identify Potential New Target in SCLC Treatment

Researchers Identify Potential New Target in SCLC Treatment | Lung Cancer Dispatch | Scoop.it

Collagen, the main building block of skin and tendons, can also contribute to suppressing cancer growth. DDR2, one of the proteins that collagen interacts with, is mutated in some cases of squamous cell carcinoma (SCC) of the lung, a type of non-small cell lung cancer (NSCLC). Researchers have found that when DDR2 is activated by collagen, it in turn activates a protein called SHP-2. It also prevents cell cultures from forming clusters, a model of tumor formation. However, mutant forms of DDR2 that occur in SCC, did not have this effect on cell cultures, and some also did not activate SHP-2, suggesting that lack of SHP-2 activation may contribute to SCC. Drugs that mimic the activity of SHP-2 may offer targeted treatments for SCC.

Cancer Commons's insight:

Institute of Cancer Research | Aug 30, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Novel Drugs Show Promise in Non-Small Cell Lung Cancer

Novel Drugs Show Promise in Non-Small Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

Medical experts at the 2012 Chemotherapy Foundation Symposium presented data on the growing number of targeted treatments for non-small cell lung cancer (NSCLC) with so-called driver mutations—specific genetic mutations that drive tumor growth. Among the drugs showing promise in adenocarcinoma are ridaforolimus for KRAS-mutant tumors, ganetespib for ALK- or KRAS-mutant tumors, and afatinib for EGFR-mutant tumors. For squamous cell carcinoma (SCC), new potential treatments include AZD4547 and BGJ398 (FGFR1-mutant), dasatinib and nilotinib (DDR2 mutant), Tarceva and Iressa (EGFRvIII-mutant), and Yervoy and Cadi-05 (all SCC), while anti–PD-1 antibodies such as BMS-936558 may be effective for both adenocarcinoma and SCC.

Cancer Commons's insight:

OncLive | Jan 14, 2013

more...
No comment yet.